関連する実験動画
Updated: Jul 18, 2026

12:08
Diagonal Method to Measure Synergy Among Any Number of Drugs
Published on: June 21, 2018
世界的な薬物ギャップ
1Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA. reich@hsph.harvard.edu
まとめ
市場の失敗と収入のギャップのために,世界的な薬物アクセス不平等が続いている. これに対処するには,研究補助金,財政的インセンティブ,および不可欠な,新しい,および将来の医薬品のための制度的改善を組み合わせた政策が必要です.
科学分野:
- グローバル・ヘルス グローバル・ヘルス
- 医薬品政策について
- 健康経済学 医療経済学
背景:
- 医薬品へのアクセスにおいて,高所得国と低所得国の間で,世界的な格差が大きい.
- これらの格差は,市場の失敗,政府の欠陥,および実質的な所得格差の組み合わせから生じている.
- 世界的な薬物格差は,不可欠な,新しい,まだ開発されていない医薬品へのアクセスに影響します.
研究 の 目的:
- グローバルな薬物ギャップに対処するための政策勧告の概要を述べる.
- 異なる介入タイプを組み合わせた多面的な政策アプローチを提案する.
- 医薬品への平等なアクセスと研究開発のインセンティブの必要性をバランスさせる.
主な方法:
- プッシュ,プル,およびプロセスアプローチを統合した政策分析の枠組み.
- 医薬品へのアクセスとイノベーションに関する既存の文献のレビュー.
- 統合された政策ソリューションの概念化.
主要な成果:
- 一つの解決策ではなく,包括的な政策枠組みが必要である.
- 政策は,医薬品の異なるカテゴリー (必須,新しい,将来の) を扱わなければならない.
- プッシュ (補助金),プル (市場保証),プロセス (制度能力) の戦略を統合することが推奨されます.
結論:
- グローバルな薬物アクセス不平等に対処するには,ターゲットを絞ったR&Dサポートと市場ベースのインセンティブの組み合わせが必要です.
- 政策の効果的な実施には,制度能力の強化が不可欠である.
- 公平なアクセスとイノベーションのインセンティブのバランスをとることは,戦略的政策設計を通じて達成可能である.
キーワード:
保健医療と公衆衛生について関連する概念動画
Drug Distribution: Overview
Drug distribution within the body is a dynamic process involving the movement of a drug in two directions across various compartments: from the bloodstream into tissues (tissue uptake) and from tissues back into the bloodstream (tissue release or redistribution). This process is passive and primarily driven by two variables: the concentration gradient between the bloodstream and the extravascular tissues and the drug's ability to cross the cell membrane.
Initially, the free drug in the...
Initially, the free drug in the...
Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

